Press release +
Lung Cancer Awareness Month 2026: Studies Confirm Benefit of Screening
Published by: Prothea Technologies
Date 20.11.26
Lung Cancer Awareness Month provides an opportunity to recognise progress in the early detection of lung cancer worldwide and the need for new technologies to diagnose and treat the growing number of patients identified through screening.
The benefits of screening were demonstrated in the landmark NELSON study1, conducted in the Netherlands and Belgium, which followed more than 15,000 participants over ten years. It found that low-dose CT screening reduced deaths from lung cancer by 24% among men compared with those who were not screened. The findings provide compelling evidence of the potential for screening to save lives.
Results from the London SUMMIT study2, were consistent with the Nelson study. Among 12,773 participants in North and East London, 261 lung cancers were identified following the first screening CT scan. Nearly 80% were diagnosed at stages I or II, and 90% of patients diagnosed received potentially curative surgery or radiotherapy.
Lung cancer remains one of the leading causes of cancer death worldwide, but the expansion of screening is changing the stage at which the disease is detected, creating opportunities for more effective treatment.
As screening identifies more small and early-stage lung cancers, clinicians need technologies that can locate these, more challenging, lesions, obtain adequate tissue samples for diagnosis and biomarker testing, and deliver effective treatment. Prothea Technologies is addressing these challenges, with a technology used with bronchoscopy, that combines real-time molecular guidance with minimally invasive lung cancer ablation – with a vision of the biopsy and treatment of lung cancer in a single hospital visit – reducing time-to-treat from weeks to minutes; relieving hospital pressures, improving patient outcomes.
Professor Kev Dhaliwal, Chief Medical and Chief Scientific Officer, Prothea Technologies, commented:
“Lung cancer screening is a breakthrough for people with a history of smoking. And we mustn’t forget that Lung cancer is not just a smoker’s disease – around 15% of people diagnosed with lung cancer have never smoked. Air pollution is a major contributor to increasing risks of lung cancer in never-smokers. Early diagnosis and therapy saves lives.”
Lung Cancer Awareness Month
November is Lung Cancer Awareness Month, supported by organisations including Macmillan Cancer Support and lung cancer charities internationally. The campaign raises awareness of symptoms, the importance of early diagnosis and the support available to people affected by lung cancer.
https://www.macmillan.org.uk/cancer-awareness/lung-cancer-awareness-month
https://www.uklcc.org.uk/about-us
https://www.lungcancercoalition.org/
About Prothea Technologies
Prothea Technologies is a private medical technology company developing a novel image-guided therapy and a vision of lung cancer biopsy and treatment in a single hospital visit.
Lung cancer is the third most common form of cancer in the U.S. and annually claims more lives than breast, prostate and colon cancer combined. Screening programmes aim to facilitate the early detection of suspicious lesions, but delivering value from these initiatives present significant challenges for hospitals already grappling with low biopsy yields and false negatives, as well as surgical costs and post-surgical complications.
Prothea Technologies, a spin-out company from the Universities of Edinburgh and Bath, in-licensed several patents from these institutions as part of a Series A financing in 2024. Prothea’s novel bronchoscopy system is initially focused on patients requiring a biopsy, with abnormal lung lesions per CT scan. The technology combines innovative microscopic optical fibres, next generation fluorescence imaging and biopsy instruments to deliver adjacent image capture and tissue characterisation at the molecular level.
A laser Ablation System is in development for the treatment of lesions immediately following visualisation and biopsy. The integration of these two systems (real-time imaging and ablation) will streamline biopsy and treatment into a single hospital visit, reducing time-to-treat from weeks to minutes, thereby relieving hospital pressures and improving patient outcomes.
The Prothea Imaging System, combining a single-use Eyes on Target Imaging & Access Catheter with KronoScan™ Label-free Molecular Imaging and the Ablation System, are in development and are not currently cleared for use in any country.
The Company’s clinical pipeline also includes a well-advanced program supported by Wellcome, for the early identification of specific lung infections in intensive care patients, enabling earlier selection of optimal drug therapy.
1Cancer Imaging, October 2011
2Lancet Oncology, March 2025